Table 1.

Baseline characteristics of included trials

Study name/first author and year of publication	Type of PCSK9 inhibitor	Treatment in no PCSK9 inhibitor	PCSK9 inhibitor (n)	No PCSK9 inhibitor (n)	Agea (years)	Male (n)	Hypertension (percentage of patients)	Diabetes mellitus (percentage of patients)	Median follow-up duration (weeks)	Baseline statin usage (percentage of patients)
FOURIER/Sabatine et al.8/2017	Evolocumab 140 mg Q2W; 420 mg Q4W + optimized lipid-lowering regimen	SC placebo Q2W or Q4W +  optimized lipid-lowering regimen	13 784	13 780	63 ± 9	20 795	80	36	114	100
GLAGOV/Nicholls et al.15/2016	Evolocumab 420 mg Q4W	SC placebo Q4W	484	484	60 ± 9	698	82	21	78	99
ODYSSEY CHOICE 1/Roth et al.16/2016	Alirocumab 75 mg Q2W; 300 mg Q4W ± statin	SC Placebo Q2W and Q4W ±  statin	573	230	61 ± 10	462	NR	27	48	68
ODYSSEY CHOICE 2/Stroes et al.17/2016	Alirocumab 75 mg Q2W; 150 mg Q4W ± statin	SC placebo Q2W	175	58	63 ± 10	130	61	16	24	0
ODYSSEY COMBO 1/Kereiakes et al.14/2015	Alirocumab 75 mg/150 mg Q2W + Max. tolerated statin + other lipid lowering therapy	SC Placebo Q2W + Max. tolerated statin + other lipid-lowering therapy	209	107	63 ± 9	208	NR	43	52	100
ODYSSEY COMBO 2/Cannon et al.10/2015	Alirocumab 75 mg Q2W + oral placebo + statin	Ezetimibe + SC placebo Q2W + statin	479	241	62 ± 9	530	NR	31	52	100
ODYSSEY FH 1/Kastelein et al.13/2015	Alirocumab 75 mg/150 mg Q2W + Max. tolerated lipid lowering therapy	SC placebo Q2W + lipid-lowering therapy	323	163	52 ± 13	274	43	12	78	100
ODYSSEY FH 2/Kastelein et al.13/2015	Alirocumab 75 mg/150 mg Q2W + Max. tolerated lipid lowering therapy	SC placebo Q2W + lipid-lowering therapy	167	82	53 ± 13	131	33	4	78	100
ODYSSEY HIGH FH/Ginsberg et al.12/2016	Alirocumab 150mg Q2W + Max. tolerated lipid-lowering therapy	SC Placebo Q2W + lipid-lowering therapy	72	35	51 ± 13	57	57	14	78	100
ODYSSEY LONG TERM/Robinson et al.5/2015	Alirocumab 150 mg Q2W + statin ± other lipid-lowering therapy	SC Placebo Q2W + statin ± other lipid-lowering therapy	1553	788	61 ± 10	1457	NR	35	78	100
ODYSSEY OPTIONS 1/Bays et al.25/2015	Alirocumab 75/150 mg Q2W + atorvastatin	Ezetimibe +  atorvastatin	104	102	63 ± 10	231	79	50	32	100
ODYSSEY OPTIONS 2/Farnier et al.11/2015	Alirocumab 75 mg/150 mg Q2W + rosuvastatin	Ezetimibe + rosuvastatin + SC placebo Q2W	103	101	61 ± 10	187	71	39	32	79
OSLER 1 and OSLER 2/Sabatine et al.9/2015	Evolocumab 140 mg Q2W; 420 mg Q4W + standard therapy	Standard therapy	2976	1489	58 ± 11	2255	52	13	48	70
TESLA/Raal et al.27/2014	Evolocumab 420 mg Q4W	SC placebo Q4W	33	16	31 ± 13	25	10	6	12	100
Yukawa 2/Kiyosue et al.26/2016	Evolocumab 140 mg Q2W; 420 mg Q4W + atorvastatin therapy	Placebo Q2W; Q4W +  atorvastatin	202	202	62 ± 11	244	74	49	12	100

Max., maximum; n, number of patients; NR, not reported; PCSK9, proprotein convertase subtilisin/kexin type 9; Q1–Q3, interquartile range; Q2W, every 2 weeks; Q4W, every 4 weeks; SD, standard deviation; SC, subcutaneous.

^aValues are mean ± SD; median (Q1–Q3).